Substitute for form 1449/PTO (Revised 07/2005)						Complete if Known								
					A	Application Number Filing Date			10/577,390					
					Fi				May 29, 2007					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)						First Named Inventor			Long					
						Group Art Unit			1644					
						Examiner Name			To Be Assigned					
Sheet	1	1 of 1				Attorney Docket Number			035784/309974					
	·			U	. S.]	PATENT D	oct	JMEN1	ΓS					
	G.:	Document Number							6D		D 0		* * ***	
Examiner Initials*	1 1	Cite No. Number - Kind Code (if known)			1	Publication Date MM-DD-YYYY App			Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages of Relevant Figure Appear			
mittais	NO.	Number - Kind Code (ii known)			IVIIV									
	L				<u> </u>		L							
						N PATENT	DC	CUMI	ENTS					
Examiner Initials	Cita	Foreign Patent Document Country Code - Number Kind Code (if known)				Publication D MM-DD-YY		.,,	of Patentee or ant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures		English Language Translation Attached	
	Cite No.				de			4						
	140.				uc			Applica						
											Appea	r		
	7	WO 02/04021 A1				01-17-2002		IDEC Pharmaceuticals		le				
	′							Corporation		.13				
	8	WO 02/22212 A2				03-21-2002		IDEC Pharmaceuticals Corporation		ls				
	9	WO 02/28480 A2				04-11-2002		Chiron Corporation						
	10	3374	WO 03/029296 A1			04-10-2003		Chiron Corporation						
<u></u>						04-10-2003								
	11	EP 1 391 464 A1			02-25-2004		Kirin Beer Kabushiki		i					
	<u> </u>							Kaisha						
					Oï	THER DOC	IIМ	ENTS						
		Τ										Engl	ish Language	
		Include name of the author (in CA								tle of the Translation				
Examiner	Cite	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volumeissue number(s), publisher, city and/or country where published.									Attached			
Initials*	No.	+	•											
	12	FUNAKOSHI, S., et al., "Differential In Vitro and In Vivo Antitumor Effects Mediated by Anti-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-												
		Cell Lymphomas," Journal of Immunology, 1996, Vol. 19, No. 2, pp. 93-101.												
	13									Trial in				
	13	Patients with Relapsed Non-Hodgkin's Lymphom												
				No. 10, pp. 3			hiioi	11a, JOH	irnai oj Ciinica	i Onc	ology,			
Examiner	.	1 12.	,, voi. 1J,	110. 10, pp. 2	200	-J4/T.			Date	1		<u> </u>		
Signature	11								Considered					
Signature									Considered	l				

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.